JP2008508279A - 腎疾患を治療するためのビタミンｄの使用 - Google Patents
腎疾患を治療するためのビタミンｄの使用 Download PDFInfo
- Publication number
- JP2008508279A JP2008508279A JP2007523596A JP2007523596A JP2008508279A JP 2008508279 A JP2008508279 A JP 2008508279A JP 2007523596 A JP2007523596 A JP 2007523596A JP 2007523596 A JP2007523596 A JP 2007523596A JP 2008508279 A JP2008508279 A JP 2008508279A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- vitamin
- composition according
- dosage form
- paricalcitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229930003316 Vitamin D Natural products 0.000 title claims abstract description 29
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims abstract description 29
- 235000019166 vitamin D Nutrition 0.000 title claims abstract description 29
- 239000011710 vitamin D Substances 0.000 title claims abstract description 29
- 150000003710 vitamin D derivatives Chemical class 0.000 title claims abstract description 29
- 229940046008 vitamin d Drugs 0.000 title claims abstract description 29
- 208000017169 kidney disease Diseases 0.000 title claims abstract description 21
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 claims abstract description 48
- 229960000987 paricalcitol Drugs 0.000 claims abstract description 47
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 25
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 24
- 229960002478 aldosterone Drugs 0.000 claims abstract description 23
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 23
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 12
- 102000015427 Angiotensins Human genes 0.000 claims abstract description 9
- 108010064733 Angiotensins Proteins 0.000 claims abstract description 9
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 19
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 19
- 229960005084 calcitriol Drugs 0.000 claims description 18
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 18
- 235000020964 calcitriol Nutrition 0.000 claims description 16
- 239000011612 calcitriol Substances 0.000 claims description 16
- 239000012190 activator Substances 0.000 claims description 7
- 102000009310 vitamin D receptors Human genes 0.000 claims description 7
- 108050000156 vitamin D receptors Proteins 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 5
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002061 ergocalciferol Drugs 0.000 claims description 4
- 235000001892 vitamin D2 Nutrition 0.000 claims description 4
- 239000011653 vitamin D2 Substances 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims 9
- 239000012730 sustained-release form Substances 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 7
- 239000006203 subcutaneous dosage form Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 108090000783 Renin Proteins 0.000 abstract description 21
- 102100028255 Renin Human genes 0.000 abstract description 18
- 230000005764 inhibitory process Effects 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 12
- 230000036454 renin-angiotensin system Effects 0.000 abstract description 12
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 2
- 239000003087 receptor blocking agent Substances 0.000 abstract description 2
- 101100209694 Danio rerio vdra gene Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 description 26
- 238000011282 treatment Methods 0.000 description 25
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 20
- 201000001474 proteinuria Diseases 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 13
- 206010061989 glomerulosclerosis Diseases 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 206010016654 Fibrosis Diseases 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 230000029142 excretion Effects 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 10
- 230000001434 glomerular Effects 0.000 description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000003463 adsorbent Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 8
- 230000002485 urinary effect Effects 0.000 description 8
- -1 Adltmin Chemical compound 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 102000005862 Angiotensin II Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 4
- 108050007957 Cadherin Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 201000000523 end stage renal failure Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000000651 myofibroblast Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 229960002051 trandolapril Drugs 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000028208 end stage renal disease Diseases 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000005086 glomerual capillary Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000000885 nephron Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 229960002256 spironolactone Drugs 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 2
- PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
- FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940077422 accupril Drugs 0.000 description 1
- 229940062352 aceon Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940092229 aldactone Drugs 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- 229940077927 altace Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940058087 atacand Drugs 0.000 description 1
- 229940000201 avapro Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 229940097633 capoten Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940097499 cozaar Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940074619 diovan Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- LXMSZDCAJNLERA-UHFFFAOYSA-N ethanethioic acid S-(10,13-dimethyl-3,5'-dioxo-7-spiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]yl) ester Chemical compound C12C(SC(=O)C)CC3=CC(=O)CCC3(C)C2CCC2(C)C1CCC21CCC(=O)O1 LXMSZDCAJNLERA-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940097708 inspra Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 229940080268 lotensin Drugs 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940103179 mavik Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940101564 micardis Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 229940118178 monopril Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 1
- 229960003693 sevelamer Drugs 0.000 description 1
- VMSRVIHUFHQIAL-UHFFFAOYSA-M sodium;n,n-dimethylcarbamodithioate Chemical compound [Na+].CN(C)C([S-])=S VMSRVIHUFHQIAL-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229940078806 teveten Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940054495 univasc Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 229940099270 vasotec Drugs 0.000 description 1
- 102000035029 vitamin receptors Human genes 0.000 description 1
- 108091005463 vitamin receptors Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/901,660 US20050148557A1 (en) | 2003-07-29 | 2004-07-28 | Use of Vitamin Ds to treat kidney disease |
| US10/974,243 US20050124591A1 (en) | 2003-07-29 | 2004-10-27 | Use of vitamin Ds to treat kidney disease |
| PCT/US2005/024446 WO2006019659A1 (en) | 2004-07-28 | 2005-07-08 | Use of vitamin ds to treat kidney disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508279A true JP2008508279A (ja) | 2008-03-21 |
| JP2008508279A5 JP2008508279A5 (enExample) | 2008-10-02 |
Family
ID=34982541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523596A Withdrawn JP2008508279A (ja) | 2004-07-28 | 2005-07-08 | 腎疾患を治療するためのビタミンｄの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050124591A1 (enExample) |
| EP (1) | EP1786407A1 (enExample) |
| JP (1) | JP2008508279A (enExample) |
| CA (1) | CA2575155A1 (enExample) |
| WO (1) | WO2006019659A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015536301A (ja) * | 2012-10-09 | 2015-12-21 | レグルス セラピューティクス インコーポレイテッド | アルポート症候群の処置方法 |
| JP2016523890A (ja) * | 2013-06-27 | 2016-08-12 | ヴィルバク | 進行性腎疾患の治療のための組成物 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007001969A1 (en) * | 2005-06-27 | 2007-01-04 | The General Hospital Corporation | Vitamin d deficiency and dialysis |
| CA2624897C (en) * | 2005-10-12 | 2017-02-14 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| EP1993559B1 (en) | 2006-02-03 | 2016-06-22 | OPKO Renal, LLC | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
| US10716798B2 (en) * | 2007-02-21 | 2020-07-21 | The Regents Of The University Of Michigan | Compositions and methods for tranquilizing heart muscle |
| HRP20231142T3 (hr) | 2007-04-25 | 2024-01-05 | Eirgen Pharma Ltd. | Kontrolirano oslobađanje 25-hidroksivitamina d |
| CA2683628C (en) * | 2007-04-25 | 2018-03-06 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| JP2010525080A (ja) | 2007-04-25 | 2010-07-22 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法 |
| CA2684778C (en) * | 2007-04-25 | 2017-09-05 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
| CA2703994C (en) * | 2007-11-06 | 2017-05-23 | The Salk Institute For Biological Studies | Use of vitamin d receptor agonists and precursors to treat fibrosis |
| US8318708B2 (en) * | 2007-11-06 | 2012-11-27 | Salk Institute For Biological Studies | Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis |
| ES2954932T3 (es) | 2008-04-02 | 2023-11-27 | Eirgen Pharma Ltd | Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados |
| US20110034426A1 (en) * | 2009-08-03 | 2011-02-10 | Wisconsin Alumni Research Foundation | Method of Preventing Renal Disease and Treating Symptoms Thereof |
| WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
| DK2702155T3 (en) | 2011-04-25 | 2017-05-01 | Regulus Therapeutics Inc | MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY |
| NZ630591A (en) | 2012-04-25 | 2017-02-24 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
| KR20150030673A (ko) | 2012-06-29 | 2015-03-20 | 위스콘신 얼럼나이 리서어치 화운데이션 | 속발성 부갑상선기능항진증을 치료하기 위한 2-메틸렌-19-노르-(20S)-1α,25-디히드록시비타민 D₃의 용도 |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| CA2909941A1 (en) | 2013-04-24 | 2014-10-30 | Salk Institute For Biological Studies | Vitamin d receptor/smad genomic circuit gates fibrotic response |
| WO2014197680A1 (en) | 2013-06-05 | 2014-12-11 | Salk Institute For Biological Studies | Vitamin d receptor agonists to treat diseases involving cxcl12 activity |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10369161B2 (en) | 2014-12-30 | 2019-08-06 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
| US9539264B2 (en) | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| CN108883120A (zh) | 2016-03-28 | 2018-11-23 | 欧普科爱尔兰环球控股有限公司 | 维生素d治疗方法 |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| ES2968898T3 (es) * | 2019-06-06 | 2024-05-14 | Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz | Método in vitro para detectar enfermedad renal |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747008B1 (en) * | 2000-06-19 | 2004-06-08 | University Of Southern California | Methods for treating and preventing alopecia |
| FR2825087B1 (fr) * | 2001-05-22 | 2005-01-14 | Galderma Res & Dev | Analogues de la vitamine d |
-
2004
- 2004-10-27 US US10/974,243 patent/US20050124591A1/en not_active Abandoned
-
2005
- 2005-07-08 WO PCT/US2005/024446 patent/WO2006019659A1/en not_active Ceased
- 2005-07-08 EP EP05769600A patent/EP1786407A1/en not_active Withdrawn
- 2005-07-08 JP JP2007523596A patent/JP2008508279A/ja not_active Withdrawn
- 2005-07-08 CA CA002575155A patent/CA2575155A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015536301A (ja) * | 2012-10-09 | 2015-12-21 | レグルス セラピューティクス インコーポレイテッド | アルポート症候群の処置方法 |
| JP2016523890A (ja) * | 2013-06-27 | 2016-08-12 | ヴィルバク | 進行性腎疾患の治療のための組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050124591A1 (en) | 2005-06-09 |
| CA2575155A1 (en) | 2006-02-23 |
| EP1786407A1 (en) | 2007-05-23 |
| WO2006019659A1 (en) | 2006-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508279A (ja) | 腎疾患を治療するためのビタミンｄの使用 | |
| US12171731B2 (en) | Methods and compositions for the treatment of steatosis-associated disorders | |
| Cheng et al. | Modulation of hypovitaminosis D-induced islet dysfunction and insulin resistance through direct suppression of the pancreatic islet renin–angiotensin system in mice | |
| Petkovich et al. | Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation | |
| US20050148557A1 (en) | Use of Vitamin Ds to treat kidney disease | |
| JP6337170B2 (ja) | ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト | |
| CA2504751C (en) | Methods for treating gastroesophageal reflux disease | |
| Xiaowei et al. | Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria | |
| US20070093459A1 (en) | Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease | |
| TW202339758A (zh) | 藉由週期性遏制醛固酮合酶治療高血壓之方法 | |
| US20060171983A1 (en) | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease | |
| Miyata et al. | Renoprotective effects of direct renin inhibition in glomerulonephritis | |
| Nakhoul et al. | Diabetic nephropathy from RAAS to autophagy: the era for new players | |
| MX2007001136A (es) | Uso de vitamina s para tratar enfermedad renal. | |
| US20050192255A1 (en) | Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease | |
| E Gullo et al. | Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy? | |
| CN100589806C (zh) | 类固醇衍生物在制备治疗血管紧张素ⅱ相关性疾病如心血管性和增生性疾病的药物中的应用 | |
| US20050074488A1 (en) | Use of vitamin Ds to down regulate the renin-angiotensin-aldosterone system | |
| WO2005011660A1 (en) | Use of vitamin d to down regulate the renin-angiotensin-aldosterone system | |
| Mendes et al. | The role of Paricalcitol in urinary albumin-to-creatinine ratio in patients with type 2 diabetes and chronic kidney disease | |
| MX2007001133A (es) | Uso de activadores de receptor de vitamina d o analogos de vitamina d para tratar enfermedades cardiovasculares. | |
| JP2008540448A (ja) | 糖尿病性腎症の治療において、スロデキシド及び血圧低下薬を用いた併用療法 | |
| WO2025125409A1 (en) | Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats | |
| Wang et al. | Naringenin Accelerates Diabetic Wound Healing Via Regulating Macrophage M2 Polarization and Efferocytosis | |
| US20170369551A1 (en) | METHODS OF TREATING IgA NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA NEPHRITIS USING A B-CELL ACTIVATING FACTOR (BAFF) INHIBITOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080707 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080707 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110224 |